Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
- PMID: 26937618
- PMCID: PMC5405628
- DOI: 10.1038/nm.4050
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Abstract
Depression is a common, devastating illness. Current pharmacotherapies help many patients, but high rates of a partial response or no response, and the delayed onset of the effects of antidepressant therapies, leave many patients inadequately treated. However, new insights into the neurobiology of stress and human mood disorders have shed light on mechanisms underlying the vulnerability of individuals to depression and have pointed to novel antidepressants. Environmental events and other risk factors contribute to depression through converging molecular and cellular mechanisms that disrupt neuronal function and morphology, resulting in dysfunction of the circuitry that is essential for mood regulation and cognitive function. Although current antidepressants, such as serotonin-reuptake inhibitors, produce subtle changes that take effect in weeks or months, it has recently been shown that treatment with new agents results in an improvement in mood ratings within hours of dosing patients who are resistant to typical antidepressants. Within a similar time scale, these new agents have also been shown to reverse the synaptic deficits caused by stress.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5405628/bin/nihms851556f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5405628/bin/nihms851556f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5405628/bin/nihms851556f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5405628/bin/nihms851556f4.gif)
Similar articles
-
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.Annu Rev Med. 2015;66:509-23. doi: 10.1146/annurev-med-053013-062946. Epub 2014 Oct 17. Annu Rev Med. 2015. PMID: 25341010 Free PMC article. Review.
-
[Antidepressants, stressors and the serotonin 1A receptor].Neuropsychopharmacol Hung. 2015 Jun;17(2):81-9. Neuropsychopharmacol Hung. 2015. PMID: 26192901 Review. Hungarian.
-
NMDA antagonist treatment of depression.Curr Opin Neurobiol. 2016 Feb;36:112-7. doi: 10.1016/j.conb.2015.11.001. Epub 2015 Dec 11. Curr Opin Neurobiol. 2016. PMID: 26687375 Review.
-
The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression.CNS Drugs. 2011 Nov 1;25(11):913-31. doi: 10.2165/11595900-000000000-00000. CNS Drugs. 2011. PMID: 22054117 Review.
-
Worried sick: antidepressants, stress, and inflammation.J Clin Psychiatry. 2007 Oct;68(10):1613-4. doi: 10.4088/jcp.v68n1021. J Clin Psychiatry. 2007. PMID: 17960979 No abstract available.
Cited by
-
Pharmacogenomics polygenic risk score: Ready or not for prime time?Clin Transl Sci. 2024 Aug;17(8):e13893. doi: 10.1111/cts.13893. Clin Transl Sci. 2024. PMID: 39078255 Free PMC article. Review.
-
Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.Neuropsychopharmacology. 2024 Jul 22. doi: 10.1038/s41386-024-01913-3. Online ahead of print. Neuropsychopharmacology. 2024. PMID: 39039139 Review.
-
Dual-specificity protein phosphatase 6 (DUSP6) overexpression reduces amyloid load and improves memory deficits in male 5xFAD mice.Front Aging Neurosci. 2024 Jun 28;16:1400447. doi: 10.3389/fnagi.2024.1400447. eCollection 2024. Front Aging Neurosci. 2024. PMID: 39006222 Free PMC article.
-
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review.Front Psychiatry. 2024 May 15;15:1394787. doi: 10.3389/fpsyt.2024.1394787. eCollection 2024. Front Psychiatry. 2024. PMID: 38812489 Free PMC article. Review.
-
Effects of esketamine and fluoxetine on depression-like behaviors in chronic variable stress: a role of plasma inflammatory factors.Front Psychiatry. 2024 May 15;15:1388946. doi: 10.3389/fpsyt.2024.1388946. eCollection 2024. Front Psychiatry. 2024. PMID: 38812484 Free PMC article.
References
-
- Whiteford HA, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575–1586. - PubMed
-
- Kessler RC, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA. 2003;289:3095–3105. - PubMed
-
- Trivedi M, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psych. 2006;163:28–40. - PubMed
-
- Gaynes B, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60:1439–1445. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical